Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A small molecule modulating heterogeneous amyloid-β isoforms improves cognitive and pathological outcomes in acute and 5XFAD Alzheimer's disease models.

Alzheimer's research & therapy·2026
Same author

Targeting Lysyl Oxidase-like 2: A Therapeutic Strategy for Idiopathic Pulmonary Fibrosis with a Novel Indolizine Derivative.

Pharmaceutics·2026
Same author

Effects of gyroid lattice relative density on wear and mechanical performance of 3D printed TPU and flexible nylon for footwear.

iScience·2026
Same author

Small Molecule Therapeutics Targeting Amyloid-β in Alzheimer's Disease: Mechanisms, Clinical Progress, and Future Strategies.

Experimental neurobiology·2026
Same author

Targeted Discovery of β‑Branched Conjugated Polyketides from Bacteria Based on Genomic and Metabolomic Hallmarks.

JACS Au·2026
Same author

Temporal and regional trends in the diagnosis and treatment of spontaneous intracranial hypotension: a systematic review.

The journal of headache and pain·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

YoungSoo Kim1,2, Illhwan Cho2, Sunhee Lee2

  • 1Amyloid Solution Inc., Seongnam, Gyeonggi-do, Korea, Republic of (South).

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

A new fluorescent compound, AS-YFluor, can detect amyloid-β42 (Aβ42) oligomers in blood plasma. This Alzheimer's disease (AD) biomarker detection tool shows promise for early AD diagnosis and monitoring disease progression.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biochemistry
  • Medical Diagnostics

Background:

  • Amyloid-β42 (Aβ42) oligomers are key neurotoxic biomarkers implicated in Alzheimer's disease (AD) pathogenesis and progression.
  • Current diagnostic tools for early-stage AD and preclinical detection of Aβ42 oligomers are limited, hindering clinical trial efficacy.
  • Novel imaging probes are crucial for elucidating the role of Aβ42 oligomers and supporting early AD diagnosis.

Purpose of the Study:

  • To introduce AS-YFluor, a novel fluorescent compound designed for selective detection of Aβ42 oligomers.
  • To evaluate the diagnostic potential of AS-YFluor in distinguishing Alzheimer's disease patients from controls using blood plasma.
  • To assess the utility of AS-YFluor in monitoring AD progression and differentiating between various cognitive states.

Main Methods:

  • In vitro assays were performed to confirm the selectivity of AS-YFluor for Aβ42 oligomers.
  • Diagnostic potential was assessed using biological samples (brain lysate, CSF, blood) from 5XFAD transgenic mice and controls.
  • AS-YFluor was applied to blood plasma samples from 165 human participants (NC, AD, MCI, non-AD dementia) to analyze fluorescence signals.

Main Results:

  • AS-YFluor demonstrated high specificity for Aβ42 oligomers, showing no cross-reactivity with other protein species or abundant blood proteins.
  • The compound effectively differentiated between samples from 5XFAD mice and controls, validating its use in biological matrices.
  • In human studies, AS-YFluor distinguished AD patients from normal controls and non-AD dementia subjects with high accuracy (>93% sensitivity and specificity for MCI vs. AD/NC).

Conclusions:

  • AS-YFluor is a novel fluorescent agent capable of selectively detecting Aβ42 oligomer levels in the blood of Alzheimer's disease patients.
  • The compound shows significant promise as a blood-based diagnostic tool for early AD detection and monitoring disease progression.
  • AS-YFluor's versatility extends to non-clinical research applications for studying oligomer behavior.